Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05267080 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Registry on Percutaneous Electrochemotherapy

Study acronym: RESPECT
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Jan 31, 2026 to Jan 23, 2026
    • Site details revised at 15 of 15 sites
    v7
  2. Study sites: 8 to 15
    • Primary completion date: Jan 2026 to Jan 31, 2026
    • Study completion date: Jan 2027 to Jan 31, 2027
    v6
  3. Study sites: 1 to 8
    • Study completion date: Jan 2028 to Jan 2027
    • Eligibility criteria expanded, about 5 words
    • Study description shortened, about 1 word
    v5
  4. Re-verified, no change to tracked fieldsv4
  5. Trial status: Not Yet Recruiting to Recruitingv3 Show 5 more changesShow less
    • Start date changed from estimate of Sep 2022 to Jan 25, 2023
    • Study sites: 0 to 1
    • Primary completion date: Sep 2025 to Jan 2026
    • Study completion date: Sep 2027 to Jan 2028
    • Eligibility criteria shortened, about 33 words
  6. Secondary endpoints: details revised at 2 of 9 entriesv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Registry on Percutaneous ElectroChemoTherapy (RESPECT) is a post-market, prospective, non-randomized, observational study aiming at evaluating the effectiveness of percutaneous electrochemotherapy (ECT) for the treatment of liver cancer.
Trial Details
NCT Number NCT05267080
Lead Sponsor Cardiovascular and Interventional Radiological Society of Europe
Conditions
(from sponsor)		 Primary Liver Cancer, Secondary Liver Cancer
Related terms Carcinoma, Hepatocellular
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov